Two Children with Early-Onset Strokes and Intractable Epilepsy, Both with CACNA1A Mutations

Kristen N Bolte1, Melissa Assaf2, Tamara Zach2

  • 1Midwestern University Arizona College of Osteopathic Medicine, Glendale, AZ, USA.

Insights

CACNA1A gene mutations can cause pediatric epilepsy, stroke, and developmental delays. Early identification of these CACNA1A mutations is crucial for effective medical management in affected children.

Area of Science:

  • Genetics
  • Neurology
  • Pediatrics

Background:

  • CACNA1A gene mutations are linked to various neurological disorders including epilepsy and migraine.
  • Ischemic strokes are rarely associated with CACNA1A gene mutations.

Observation:

  • Two unrelated pediatric patients presented with seizures, intractable epilepsy, ischemic stroke, and developmental delays.
  • Whole exome sequencing identified distinct de novo pathogenic mutations in the CACNA1A gene in both patients.

Findings:

  • The identified CACNA1A mutations, including a novel one, resulted in similar severe phenotypes in both unrelated children.
  • This suggests a genotype-phenotype correlation where CACNA1A mutations can manifest as early-onset epilepsy and stroke.

Implications:

  • Pediatric patients with ischemic stroke and seizures warrant evaluation for CACNA1A gene mutations.
  • Prompt diagnosis of CACNA1A-related disorders facilitates targeted medical interventions and management strategies.

Related Concept Videos

Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
683
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
304
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
629
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1000
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
473
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
710